The What Works Clearinghouse (WWC) identifies studies that provide credible and reliable evidence of a given intervention’s effectiveness. Yet there is a high potential for serious estimation bias ...

Subjective cognition in chimeric antigen receptor T-cell therapy recipients. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full text component.

CHICAGO – Loxo Oncology Inc.'s announcement that it will seek tissue-agnostic approval for larotrectinib (LOXO-101) based on data that were presented at this year's ASCO meeting came just weeks after ...

The clinical development plan is a blueprint that brings a new drug discovery from preclinical development to market approval. It helps to regulate the process of drug discovery, ensuring patient ...